Clinical trials: Alzheimer's Dementia (AD)
Alzheimer Dementia, Alzheimer Disease
SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate
This is a single-center first-in-human single-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers.
- Trial name
- NCT03944460
- Testing
- Contraloid
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Prof. Dr. Dieter Willbold
Alzheimer Disease
Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life
Therapeutic education expands in Alzheimer's Disease management in France. Several studies revealed a positive impact on caregiver's burden and/or quality of life.
- Trial name
- THERAD (NCT01796314)
- Testing
- Therapeutic Educational Program
- Where
- France
- Volunteers
- 170 people
- Sponsor
- University Hospital, Toulouse
Alzheimer's Disease, MCI Due to AD
Language, Speech and Motor Function in MCI Due to AD and Alzheimer's Disease
The goal of this observational cross-sectional study is to explore the characteristics of language, speech, and motor function in persons with Mild Cognitive Impairment due to Alzheimer's disease ("MCI due to AD") and persons…
- Conditions
- Alzheimer's Disease, MCI Due to AD, Dementia Alzheimers
- Trial name
- NCT06508268
- Testing
- GAITRite walkway system OR 4-meter walking speed test, Jamar hand dynamometer, Picture description task
- Where
- Netherlands
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Hanze University of Applied Sciences Groningen
Mild Alzheimer's Disease
pBFS Guided rTMS Treating Mild Alzheimer's Disease(AD)
This study aims to investigate the effectiveness and safety of rTMS treatment under the guidance of personalized Brain Functional Sectors (pBFS) for the cognitive ability of patients with mild Alzheimer's disease.
- Trial name
- NCT05872243
- Testing
- active rTMS
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Changping Laboratory
Mild and Moderate Alzheimer's Disease, Cognitively Healthy People
An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population
Difference in nutritional status between patients with mild and moderate Alzheimer's Disease (AD) and cognitively intact healthy people in an Asian population
- Trial name
- NCT02249468
- Where
- Singapore
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Danone Nutricia Research
Dementia, Alzheimer's Disease
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.
- Trial name
- NCT00104273
- Testing
- Rasagiline
- Where
- 58 sites in United States, Australia and 2 more
- Volunteers
- 376 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Neurodegenerative Diseases
Pilot Study About Extra Virgin Olive Oil "Coratina" in Mild Cognitive Impairment and Alzheimer's Disease Patients
Alzheimer's Disease is a neurodegenerative disease age related caused by neurofibrillary tangles misfolding and Beta-amyloid protein accumulation.
- Trial name
- EVOCAD (NCT04229186)
- Testing
- EVOO-C, ROO
- Volunteers
- 24 people
- Sponsor
- University of Bari Aldo Moro
Alzheimer's Dementia (AD), Family Caregivers
Long-term Follow-up of Patients Included in the EYE-TAR(MA) Study.
EYE-TAR(MA)-Follow-Up is a non-interventionel, long-term follow-up study in subjects who participated to the study referred as EYE-TAR(MA) (NCT04730440) EYE-TAR(MA)-Follow-Up aims to evaluate the long-term impacts of the Training…
- Trial name
- NCT05254873
- Testing
- Long term follow-up
- Where
- Monaco
- Volunteers
- 7 people
- Sponsor
- Association de Recherche Bibliographique pour les Neurosciences
Loneliness
Reduce Loneliness in Care Partners of Persons With AD/ADRD
More than 60% of care partners of persons with AD/ADRD report feeling lonely. Building on the existing evidence that increasing meaning and purpose in life is a strong predictor of decreased loneliness, interventions to reduce…
- Trial name
- NCT05460494
- Testing
- RELOAD-C
- Where
- 4 sites in United States
- Volunteers
- 96 people
- Sponsor
- Northwell Health
Autosomal Dominant Cases of Alzheimer 's Disease
Genetics of Mendelian Forms of Young Onset Alzheimer Disease
Genetics of mendelian forms of young onset Alzheimer Disease (GMAJ project) Introduction : Autosomal dominant forms of Alzheimer disease (AD) are characterized by young age of onset.
- Trial name
- GMAJ (NCT01622894)
- Testing
- Genetic-Tailored AntiThrombotic Strategy
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Rouen
Alzheimer Disease
Transcranial Pulse Stimulation (TPS) for Alzheimer's Disease (AD)
This is a prospective open comprehensive proof-of-principle pilot study.
- Trial name
- NCT04333329
- Testing
- NEUROLITH
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Storz Medical AG
Mild Cognitive Impairment
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
To investigate whether [18F]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
- Trial name
- NAV4-04 (NCT01812213)
- Testing
- [18F]NAV4694
- Where
- 11 sites in United States
- Volunteers
- 76 people
- Sponsor
- Navidea Biopharmaceuticals
Mild Cognitive Impairment (MCI), Mild Alzheimer Disease
iTBS in MCI and Mild AD
This study aims to examine the effects of iTBS on cognitive function in individuals with MCI or mild AD, with a secondary objective of exploring prefrontal TBS mechanisms for cognitive function and the effect of iTBS on BDNF.
- Trial name
- NCT06670820
- Testing
- Active rTMS
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Defense Medical Center, Taiwan
Mild Cognitive Impairment, Alzheimer Disease
Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD
The purpose of this study is to evaluate the safety and tolerability of allopregnanolone, a naturally occurring brain steroid, in mild cognitive impairment and early Alzheimer's disease participants.
- Trial name
- Allo (NCT02221622)
- Testing
- Allopregnanolone injection (intravenous solution)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Southern California
Alzheimer's Disease
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD.
- Trial name
- NCT02423200
- Testing
- VX-745
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Mild Cognitive Impairment, Alzheimer Disease
Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure
The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder
- Trial name
- SHARED III (NCT05584241)
- Testing
- Diagnostic Disclosure Protocol, Biomarker Disclosure Protocol
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Michigan
Alzheimer Disease, Battery
Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development
The early assessment of new drugs for Alzheimer's disease remains difficult because of the lack of predictive end-point. The use of a battery including different parameters could improve this early development of new drugs.
- Trial name
- PharmacogWP3 (NCT01487395)
- Testing
- Donepezil .
- Where
- 3 sites in France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Alzheimer's Disease (AD)
Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
This phase 4 study will explore, in the context of the present French clinical practice, the impact of florbetaben 18F (FBB) in patients evaluated for AD who require a biomarker for etiologic determination of the cognitive and…
- Trial name
- NCT02681172
- Testing
- Neuraceq (florbetaben 18F), PET
- Where
- France
- Volunteers
- 218 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer Disease
The Effect of Repeated Transcranial Magnetic Stimulation on Off-line Resting Electroencephalographic Signal in Alzheimer's Disease
The purpose of this study is to examine whether the rTMS (repetitive Transcranial Magnetic Stimulation) could change cortical excitability measured by off-line EEG in Alzheimer's Disease (AD) patients.
- Trial name
- NCT01970150
- Testing
- rTMS real
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Alzheimer Disease
Raloxifene for Women With Alzheimer's Disease
This is a multisite pilot randomized trial of raloxifene or placebo for the treatment of women with Alzheimer's disease.
- Trial name
- NCT00368459
- Testing
- raloxifene
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Stanford University